PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Consensus Rating of “Hold” from Brokerages

Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) have been assigned a consensus recommendation of “Hold” from the fourteen analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $40.8182.

Several research firms recently issued reports on PRCT. Oppenheimer reissued a “market perform” rating on shares of PROCEPT BioRobotics in a research note on Thursday, February 26th. Wells Fargo & Company cut their price target on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a research note on Thursday, February 26th. Wall Street Zen cut shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Piper Sandler lowered their price objective on shares of PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating for the company in a research note on Thursday, February 26th. Finally, UBS Group initiated coverage on shares of PROCEPT BioRobotics in a report on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective for the company.

PROCEPT BioRobotics Stock Down 4.3%

Shares of NASDAQ PRCT opened at $24.17 on Wednesday. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -14.13 and a beta of 1.02. The company has a quick ratio of 5.77, a current ratio of 6.85 and a debt-to-equity ratio of 0.14. PROCEPT BioRobotics has a 52-week low of $19.35 and a 52-week high of $66.85. The business’s 50 day moving average is $28.96 and its two-hundred day moving average is $32.71.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.The firm had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $93.70 million. During the same quarter in the prior year, the business earned ($0.35) earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Research analysts predict that PROCEPT BioRobotics will post -1.75 EPS for the current year.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, EVP Alaleh Nouri sold 6,892 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $23.70, for a total value of $163,340.40. Following the completion of the transaction, the executive vice president owned 114,264 shares of the company’s stock, valued at $2,708,056.80. This trade represents a 5.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Antal Rohit Desai purchased 167,246 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was acquired at an average price of $25.58 per share, with a total value of $4,278,152.68. Following the purchase, the director owned 167,246 shares of the company’s stock, valued at approximately $4,278,152.68. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 426,262 shares of company stock valued at $10,483,091 in the last 90 days. Company insiders own 17.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Advisory Services Network LLC increased its holdings in PROCEPT BioRobotics by 1.3% during the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after purchasing an additional 250 shares during the period. Vega Investment Solutions boosted its stake in shares of PROCEPT BioRobotics by 52.0% in the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock valued at $45,000 after buying an additional 265 shares during the period. Frank Rimerman Advisors LLC grew its position in shares of PROCEPT BioRobotics by 0.3% during the third quarter. Frank Rimerman Advisors LLC now owns 122,389 shares of the company’s stock worth $4,368,000 after buying an additional 307 shares in the last quarter. RiverPark Advisors LLC grew its position in shares of PROCEPT BioRobotics by 22.5% during the second quarter. RiverPark Advisors LLC now owns 1,761 shares of the company’s stock worth $101,000 after buying an additional 324 shares in the last quarter. Finally, Osaic Holdings Inc. increased its stake in shares of PROCEPT BioRobotics by 20.3% during the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock worth $115,000 after buying an additional 337 shares during the period. 89.46% of the stock is owned by institutional investors and hedge funds.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed large open‑market purchases (roughly $10M+ of stock across March 5–9), increasing his stake markedly — a strong insider vote of confidence that can support the share price. Read More.
• Positive Sentiment: Research coverage was started at Robert W. Baird (coverage can increase visibility and trading interest); that may help liquidity and analyst engagement. Read More.
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold modest stakes (~6.7k and ~6.9k shares on March 6); small insider sales can be personal liquidity and are smaller in scale than the director’s purchases. Read More.
• Negative Sentiment: Multiple law firms (Glancy Prongay Wolke & Rotter, Pomerantz, Frank R. Cruz, Levi & Korsinsky and others) have announced securities‑fraud investigations into PRCT, citing prior guidance/comments on revenue and handpiece pricing — this raises litigation risk, potential disclosures or restatements, and near‑term downward pressure on sentiment. Read More.
• Negative Sentiment: Recent quarterly results (Feb. 25) missed consensus: EPS and revenue came in below expectations — a key fundamental headwind that likely prompted analyst target downgrades and is feeding the ongoing scrutiny. Read More.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.